102792-10-9

Basic information

• Product Name: 1H-Imidazole, 2,4-dimethyl-1-(3-methyl-4-nitrophenyl)-
• CAS NO: 102792-10-9
• Molecular Formula: C12H13N3O2
• Molecular Weight: 231.254
• Mol File: 102792-10-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Imidazole, 2,4-dimethyl-1-(3-methyl-4-nitrophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole, 2,4-dimethyl-1-(3-methyl-4-nitrophenyl)-(102792-10-9)
• EPA Substance Registry System: 1H-Imidazole, 2,4-dimethyl-1-(3-methyl-4-nitrophenyl)-(102792-10-9)

Safety Data

• Hazardous Substances Data: 102792-10-9(Hazardous Substances Data)

Upstream product

• 930-62-1 2,4-Dimethylimidazole 
• 446-33-3 5-Fluoro-2-nitrotoluene 

Downstream Products

• 102792-03-0 1-(4-Amino-3-methylphenyl)-2,4-dimethylimidazole 
• 108857-38-1 1-(4-amino-3-cyano-5-methylphenyl)-2,4-dimethylimidazole 
• 108857-39-2 1-(4-Amino-3-bromo-5-methylphenyl)-2,4-dimethylimidazole 
• 118111-97-0 1-(4-Acetamido-3-acetyl-5-methylphenyl)-2,4-dimethylimidazole 
• 102791-97-9 (E)-N-[4-(2,4-Dimethyl-imidazol-1-yl)-2-methyl-phenyl]-3-ethoxy-acrylamide 
• 102791-47-9 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2(1H)-quinolinone 
• 118111-98-1 1-(3-Acetyl-4-amino-5-methylphenyl)-2,4-dimethylimidazole 
• 120906-35-6 trans-1-<4-(3-Ethoxypropenamido)-3-methylphenyl>-5-acetyl-2,4-dimethylimidazole 
• 111539-73-2 1-(4-Amino-3-methylphenyl)-5-cyano-2,4-dimethylimidazole 
• 111539-72-1 5-Acetyl-1-(4-amino-3-methylphenyl)-2,4-dimethylimidozole 
• 111539-74-3 1-(4-Amino-3-methylphenyl)-5-iodo-2,4-dimethylimidazole 

Relevant articles and documents

2(1H)-Quinolinones with Cardiac Stimulant Activity. 3. Synthesis and Biological Properties of 6-Imidazol-1-yl Derivatives

A series of 6-imidazol-1-yl-8-methyl-2(1H)-quinolinones was synthesized and evaluated for cardiac stimulant activity in dogs.The majority of compounds were prepared from an appropriate 6-imidazol-1-yl-2(1H)-quinolinone precursor or by sulfuric acid cataly

6-heteroaryl quinolone inotropic agents

A series of novel heterocyclic-substituted 2-(1H)-quinolone compounds have been prepared, including the 3,4-dihydro derivatives thereof, wherein the heterocyclic ring moiety is a pyrrolyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl group attached by a nitrogen atom of said group to the 5-, 6-, 7- or 8-positions of the quinolone ring. These particular compounds are useful in therapy as highly potent inotropic agents and therefore, are of value in the treatment of various cardiac conditions. Preferred member compounds include 6-(2,4-dimethylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, 6-(2,4-dimethyl-5-nitroimadazol-1-yl)-8-methyl-2-(1H)-quinolone, 8-methyl-6-(tetrazol-1-yl)-2-(1H)-quinolone, 8-methyl-6-(1,2,4-triazol-4-yl)-2-(1H)-quinolone, and 6-(4-cyano-2-methylimidazol-1-yl)-8-methyl-2-(1H)-quinolone, respectively. Methods for preparing these compounds from known starting materials are provided.